EUVIMEDEUVIMED entdecken
Open Access

Impact of Low-Frequency Human Immunodeficiency Virus Type 1 Drug Resistance Mutations on Antiretroviral Therapy Outcomes

Rachel M Burdorf, Shuntai Zhou iD, Claire Amon, Nathan Long, Collin S Hill, Lily Adams, Gerald Tegha, Maganizo B Chagomerana, Allan Jumbe, Madalitso Maliwichi, Shaphil Wallie, Yijia Li iD und 2 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Rachel M Burdorf und 13 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, National Institute of Allergy and Infectious Diseases, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The association between low-frequency human immunodeficiency virus type 1 (HIV-1) drug resistance mutations (DRMs) and treatment failure (TF) is controversial. We explore this association using next-generation sequencing (NGS) methods that accurately sample low-frequency DRMs.

Methods

We enrolled women with HIV-1 in Malawi who were either antiretroviral therapy (ART) naive (cohort A), had ART failure (cohort B), or had discontinued ART (cohort C). At entry, cohorts A and C began a nonnucleoside reverse transcriptase inhibitor–based regimen and cohort B started a protease inhibitor–based regimen. We used Primer ID MiSeq to identify regimen-relevant DRMs in entry and TF plasma samples, and a Cox proportional hazards model to calculate hazard ratios (HRs) for entry DRMs. Low-frequency DRMs were defined as ≤20%.

Results

We sequenced 360 participants. Cohort B and C participants were more likely to have TF than cohort A participants. The presence of K103N at entry significantly increased TF risk among A and C participants at both high and low frequency, with HRs of 3.12 (95% confidence interval [CI], 1.58–6.18) and 2.38 (95% CI, 1.00–5.67), respectively. At TF, 45% of participants showed selection of DRMs while in the remaining participants there was an apparent lack of selective pressure from ART.

Conclusions

Using accurate NGS for DRM detection may benefit an additional 10% of patients by identifying low-frequency K103N mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsDrug Resistance, ViralMutationTreatment FailureHumansFemaleAdultMalawiAnti-HIV AgentsHigh-Throughput Nucleotide SequencingCohort StudiesYoung AdultTreatment Outcome

Stichwörter der Autor:innen

antiretroviral therapydrug resistance mutationslow-frequency mutationnext generation sequencingtreatment outcome

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Lineberger Comprehensive Cancer Center.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill.
  • UNC Project-Malawi, Lilongwe.
  • Department of Medicine, University of North Carolina at Chapel Hill.
  • Department of Medicine, University of Pittsburgh Medical Center, Pennsylvania.
  • Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill.

ORCID-Profile: Shuntai Zhou, Yijia Li

Förderung

  • NICHD NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NCI NIH HHS
  • NIH HHS
  • NIAID NIH HHS
  • UNC Lineberger Comprehensive Cancer Center
  • National Institutes of Health

Zitieren

APA

Burdorf, R. M., Zhou, S., Amon, C., Long, N., Hill, C. S., Adams, L., Tegha, G., Chagomerana, M. B., Jumbe, A., Maliwichi, M., Wallie, S., Li, Y., Swanstrom, R., & Hosseinipour, M. C. (2024). Impact of Low-Frequency Human Immunodeficiency Virus Type 1 Drug Resistance Mutations on Antiretroviral Therapy Outcomes. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae131

Vancouver

Burdorf RM, Zhou S, Amon C, Long N, Hill CS, Adams L, et al. Impact of Low-Frequency Human Immunodeficiency Virus Type 1 Drug Resistance Mutations on Antiretroviral Therapy Outcomes. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae131

BibTeX
@article{Burdorf2024,
  author = {Burdorf, Rachel M and Zhou, Shuntai and Amon, Claire and Long, Nathan and Hill, Collin S and Adams, Lily and Tegha, Gerald and Chagomerana, Maganizo B and Jumbe, Allan and Maliwichi, Madalitso and Wallie, Shaphil and Li, Yijia and Swanstrom, Ronald and Hosseinipour, Mina C},
  title = {Impact of Low-Frequency Human Immunodeficiency Virus Type 1 Drug Resistance Mutations on Antiretroviral Therapy Outcomes},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae131}
}
Kostenlos starten →